Abstract
Abstract
Purpose
The aim of the current study was to molecularly determine Bcl-2 and BAX gene mutations in HPV-associated squamous cell carcinoma of the cervix.
Methods
Formalin-fixed, paraffin-embedded tissue blocks, all consisting of squamous cell carcinoma of the cervix, were used for this study. The nucleic acid amplification technique and various steps for DNA sequencing, including DNA extraction and polymerase chain reaction, were used.
Results
Mutations were detected in the Bcl-2 gene of patients with squamous cell carcinoma of the cervix in the 10–860 bp region, while BAX gene mutations were detected in the 10–320 bp region. The nucleotide mutations in the Bcl-2 gene were A > G (50%), C > T (33.33%), and G > A > T (16.67%), while the BAX gene mutations were A > (16.67%), T > (16.67%), G > (16.67%), A > C (16.67%), T > G (16.67%), and T > C (16.67%). The mutations in the BAX gene were Indel (50%), Transversion (33.4%), and Transition (16.6%), while only the Transition mutation (100%) was detected in the Bcl-2 gene. The functional mutations in the BAX gene were only missense mutations (100%), but in the Bcl-2 gene, the functional mutations were missense (50%) and silent (50%) mutations.
Conclusion
Our findings revealed genomic mutations of different types and frequencies in the BAX and Bcl-2 genes in squamous cell carcinoma of the cervix, which should encourage further research to better understand these mutations and exploit them for clinical use.
Publisher
Springer Science and Business Media LLC
Reference31 articles.
1. Borrero LJH, El-Deiry WS. Tumor suppressor p53: biology, signaling pathways, and therapeutic targeting. Biochim Biophys Acta Rev Cancer. 2021;1876(1):188556.
2. Carpenter R, Brady MF. BAX Gene. In: StatPearls. Treasure Island : StatPearls Publishing; 2023; Available from: https://www.ncbi.nlm.nih.gov/books/NBK555927/.
3. Ekundina VO, Awopetu V, Oladoye O, Alabi O, Iyiola S. BAX and BCL-2 gene mutation signatures of benign and malignant lesions of the breast. Ann Med Health Sci Res. 2023;13(3):451–7.
4. Ekundina VO, Ayowole OF, Ejelue CC, Oladele AA, Sanya O, Eze GI. Assessment of P53 BCL-2 and CD34 in premalignant and malignant cervical lesions. J Krishna Institute Med Sci Uni. 2022;11(2):31–45.
5. Ekundina VO, Oladele AA, Wilson H, Hassan N, Sanya J. Diagnostic Utility of BCL-2, E-Cadherin and PSA in the progression of malignant prostatic lesions. International Journal of Medical Laboratory Research. 2021;6(1):1–10.